Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01674621 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study of BA058 (Abaloparatide) Transdermal Delivery in Postmenopausal Women With Osteoporosis
A Phase 2 study, sponsored by Radius Health.
- Completed
- Registry status
- Phase 2
- Development phase
- 250
- Enrollment target
NCT01674621: Completed Phase 2 study, sponsored by Radius Health.
NCT01674621 is a Phase 2 study that has completed, run by Radius Health. The registered enrollment target is 250 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (88% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01674621, a Phase 2 study, has completed, sponsored by Radius Health.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 250 participants
- Enrollment target
Study Summary
To determine the clinical safety and efficacy of abaloparatide transdermal in otherwise healthy postmenopausal women with osteoporosis as assessed by changes in bone mineral density (BMD) and serum markers of bone metabolism when compared to transdermal placebo and abaloparatide injection for 6 months of treatment.
Primary Outcome
Percent change in BMD as specified by dual energy x-ray absorptiometry (DXA) scans of the lumbar spine.
Interventions
- DRUG Abaloparatide Transdermal (50 mcg)
- DRUG Abaloparatide Transdermal (100 mcg)
- DRUG Abaloparatide Transdermal (150 mcg)
- DRUG Abaloparatide Injection (80 mcg)
- DRUG Abaloparatide Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2012-09-25 |
| Est. Completion | 2013-08-02 |
| Phase | Phase 2 |
What the finished NCT01674621 record still lists
NCT01674621 is an interventional study that assigns participants to a tested intervention. The registered 250 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (88% higher).
The record links to 0 conditions, and to 5 interventions - of which Abaloparatide Transdermal (50 mcg) is the first listed.
NCT01674621 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01674621 about?
NCT01674621 is a clinical study titled "Phase 2 Study of BA058 (Abaloparatide) Transdermal Delivery in Postmenopausal Women With Osteoporosis". To determine the clinical safety and efficacy of abaloparatide transdermal in otherwise healthy postmenopausal women with osteoporosis as assessed by changes in bone mineral density (BMD) and serum markers of bone metabolism when compared to transdermal placebo and abaloparatide injection for 6 mont...
What is the current status of trial NCT01674621?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 250 participants. The study started on 2012-09-25. Estimated completion is 2013-08-02.
What interventions are being tested in trial NCT01674621?
The interventions under investigation include: Abaloparatide Transdermal (50 mcg) (DRUG), Abaloparatide Transdermal (100 mcg) (DRUG), Abaloparatide Transdermal (150 mcg) (DRUG), Abaloparatide Injection (80 mcg) (DRUG), Abaloparatide Placebo (DRUG).
Who is sponsoring clinical trial NCT01674621?
This trial is sponsored by Radius Health, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01674621's enrollment target sits among peer trials
250 222nd of 2000 higher than 1,768 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00483249 · 250 participants · NA
Endovascular Exclusion of Thoracoabdominal and/or Paravisceral Abdominal Aortic Aneurysm
- NCT00777712 · 250 participants
Mechanisms Underlying Impaired Diabetic Wound Healing
- NCT01451502 · 250 participants · NA
Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units
- NCT01771718 · 250 participants
Pilot Study on In-vivo Non-invasive Skin Imaging Using Multiphoton Microscopy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI